Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
22972-55-0C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(O)cc1CCCCCYWEZXUNAYVCODW-RBUKOAKNSA-N22972-55-0DTXSID10945675CHEMBL499876CHEBI:197013Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungAbnormal cannabidiol is a synthetic cannabidiol agonist of GPR55 (EC50 = 2.5 μM in a GTPγS binding assay). It is selective for GPR55 over cannabinoid (CB) receptor 1 (CB1) and CB2 (EC50s = >30 μM for both in GTPγS binding assays). It is also a full agonist at GPR18, with an EC50 value of 0.835 μM for inducing p44/42 MAPK phosphorylation in HEK293 cells expressing GPR18. Abnormal cannabidiol increases migration of BV-2 microglial cells (EC50 = 0.6 μM). It induces endothelium-dependent vasodilation via a CB1-CB2-NO-independent mechanism and inhibits vasoconstriction induced by endothelin 1 (ET-1; ) in retinal arterioles, an effect that can be blocked by the calcium-sensitive potassium channel blocker apamin . Abnormal cannabidiol also decreases blood pressure in anesthetized rats when administered intravenously at a dose of 20 μg/g or when administered directly into the rostral ventrolateral medulla at 0.4 and 0.8 μg.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…